-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Min Wu et al.
of the Department of Chemical and Biomolecular Engineering of the National University of Singapore constructed nanoparticle TCFNP@iRGD for photoacoustic imaging of GBM in a mouse model derived from intracranial transplantation of glioma patients, and the material showed excellent GBM detection performance in vitro and in vivo.
The results were published online in the September 2022 issue of Advanced Healthcare Materials
.
- Excerpted from the article chapter
【Ref: Wu M, et al.
Adv Healthc Mater.
2022 Nov; 11(21):e2201640.
doi: 10.
1002/adhm.
202201640.
Epub 2022 Sep 1.
】
Research background
CT and MRI are currently the main tools for clinical diagnosis of glioblastoma (GBM), but there are still disadvantages
such as radiation risks and cumbersome procedures.
As a non-invasive imaging mode, photoacoustic (PA) imaging can retain its strong optical contrast, height resolution and real-time visual advantages according to exogenous PA contrast agent, and become a potential GBM diagnostic method
during preoperative operation.
Min Wu et al.
of the Department of Chemical and Biomolecular Engineering of the National University of Singapore constructed nanoparticle TCFNP@iRGD for photoacoustic imaging of GBM in a mouse model derived from intracranial transplantation of glioma patient cells (GPDCs), and the material showed excellent GBM detection performance in vitro and in vivo.
The results were published online in the September 2022 issue of Advanced Healthcare Materials
.
Research methods
The authors used nanoprecipitation combined with organic small molecule PA contrast agent [2-(3-cyano-4,5,5-trimethylfuran-2(5H)-subunit)malononitrile (TCF)-OH] to construct PA imaging nanomaterials (NPs) (TCFNP@iRGD).
At the same time, in the in situ tumor-bearing mouse model of glioblastoma, MRI and PA imaging were used to image and compare
the intracranial tumors of the model.
Study results
The results show that TCFNP synthesized by nanoprecipitation has similar physical properties to TCFNP@iRGD, including particle size and absorption peak
.
The PA signal generation performance of TCFNP@iRGD is concentration-dependent and has excellent photostability
.
The authors found that after incubation TCFNP@iRGD with GBM cells, red fluorescence from hyaluronic acid and green fluorescence from TMRMA-iRGD were exhibited, and the two fluorescence could be well combined, and tumor cells could successfully take up TCFNP@iRGD
.
The authors used tumor multicellular spheroid models (MCS) to further study the penetration of the material, and the results showed that iRGD modification can help NPs penetrate into the MCS core
.
The authors embedded 3D MCS cells in the gel and evaluated the PA signal by a real-time photoacoustic imaging system; It was found that the treated MCS cells TCFNP@iRGD had a stronger PA mapping signal
than TCFNP.
.
Finally, in the GPDC intracranial xenograft mouse model, the authors injected the material through the tail vein and imaged it by photoacoustic imaging system, and found that the PA signal intensity of the brain tumor region of the TCFNP@iRGD group was much higher than that of the TCFNP group, which proved that iRGD modification was given to brain tumor targeting performance and TCFNP@iRGD excellent PA imaging performance (Figure 1).
Figure 1.
TCFNP@iRGD in vivo PA imaging
in GPDC intracranial xenograft mouse model.
Conclusion of the study
In summary, organic small molecule contrast agents were used to design and construct GBM tumor targeting material TCFNP@iRGD to achieve excellent performance
in vivo and in vitro detection of GBM.
As the first report on GBM photoacoustic imaging based on GPDC intracranial xenograft mouse model, this research result realizes the PA imaging performance of detecting GBM tumor specificity, which proves that the material has broad application potential
in the clinical diagnosis of GBM.
